<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431833</url>
  </required_header>
  <id_info>
    <org_study_id>1986-001</org_study_id>
    <secondary_id>TR701-124</secondary_id>
    <nct_id>NCT01431833</nct_id>
  </id_info>
  <brief_title>A PK and Safety Study in Subjects With Hepatic Impairment</brief_title>
  <official_title>A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the single dose PK and safety of TR701 FA in subjects with Moderate or Severe hepatic
      impairment versus matched control subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the single-dose pharmacokinetics (PK) and safety of TR-701 free acid
      (FA) in subjects with Moderate or Severe hepatic impairment compared with matched control
      subjects with normal hepatic function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>PK Assessment in moderate and severe hepatic impairment and matched controls.PK Assessments include plasma parameters maximum observed concentration (Cmax), time to occurrence of Cmax, area under the plasma concentration-time curve from Hour 0 to the last measurable concentration(AUC0-t), area under the plasma concentration-time curve from Hour 0 extrapolated to infinity (AUC0-∞)and systemic clearance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>7 days</time_frame>
    <description>Safety Assessments evaluated through adverse events, laboratory evaluations (hematology and chemistry), vital signs, ECGs, and physical examinations, in moderate and severe hepatic impairment and matched controls.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Moderate hepatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA</intervention_name>
    <description>Oral single dose 200 mg</description>
    <arm_group_label>Moderate hepatic</arm_group_label>
    <arm_group_label>Severe Hepatic</arm_group_label>
    <arm_group_label>Matched control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate or severe hepatic impairment or matched control

          -  BMI between 18.0 and 40.0 kg/m2

        Exclusion Criteria:

          -  Evidence of acute deterioration of hepatic function within 8 weeks

          -  ALT or AST ≥ 5 times upper limit of normal for moderates; ALT or AST ≥ 8 times upper
             limit of normal for severes

          -  Total bilirubin &gt; 5 mg/dl for moderates; no upper limit for severes

          -  Hemoglobin &lt; 10g/dl for moderates; Hemoglobin &lt; 9g/dl for severes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillippe G Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Investigator Site 001</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Investigator Site 002</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Matched control subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

